CSF2 and myeloid sarcoma: Recent studies have shown increased frequencies of GM-CSF+ Th cells in the periphery and cerebrospinal fluid (CSF) of MS patients compared to healthy individuals, and treatments with some immunomodulatory therapies, such as rIFN-β, normalize their numbers (29–32).